IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer: https://lnkd.in/gWX_6n3z
IDEAYA Biosciences’ Post
More Relevant Posts
-
WATCH: Following ASCO GU 2024, a panel of GU medical oncologists discuss recent updates in bladder cancer and provide comprehensive insights on the evolving treatment landscape. #GU24 #oncology https://lnkd.in/eHmfnAwi
To view or add a comment, sign in
-
Experts discuss oral SERDs in the pipeline, clinical pathways for treatment of breast cancer, and strategies to help ensure patients have access to treatment. They also offer perspectives on diverse agents in development, including their toxicity profiles. Watch the #PeerExchange series here: https://bit.ly/3WdkGsj #ManagedCare #BreastCancer
Advances in Therapy for ER+/HER2- Metastatic Breast Cancer
ajmc.com
To view or add a comment, sign in
-
The data from 27,010 participants, 45-85YO, showed PREEMPT blood-based CRC test had sensitivity 80.5%, specificity 91.5% for non-advanced colorectal neoplasia at CMS’s NCD recommended cutoff of 90%. 12.5% sens for advanced adenomas, and 29% sens for Stage 0. When powered at 96%+, sens 79.2%, spec 91.5%. Stage I: 57.1%, II: 100%, III: 82.4%, IV: 100%. Important part: Freenome has already collected study data to improve the test. The sample size can be increased by >59%.
Today, we announced topline results from our PREEMPT CRC Study, the largest clinical study to validate a blood-based test for the early detection of colorectal cancer. Read more in the press release here: https://lnkd.in/gr3PgG89
To view or add a comment, sign in
-
Passionate Medical Oncologist | Assistant Lecturer at National Cancer Institute | ESMO Certified | ESCO Graduate |ESGO member| ASCO Member | Dedicated to Improving Patient QOL and Outcomes.
1st ADC in ovarian cancer
Mirvetuximab soravtansine monotherapy led to an objective response rate of 51.9% in heavily pretreated patients with FRα+, platinum-sensitive ovarian cancer, meeting the primary end point of the phase 2 PICCOLO trial. #GYNCSM https://lnkd.in/eJtiWjfe
Phase 2 Study of Mirvetuximab in Ovarian Cancer Meets Primary End Point
To view or add a comment, sign in
-
A panel of medical oncologists discuss got together to provide updates in bladder cancer and provide comprehensive insights on the evolving treatment landscape following ASCO #GU2024. #oncology https://lnkd.in/eBhjBhZZ
Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer (MIBC)
onclive.com
To view or add a comment, sign in
-
About 7-Methoxyflavone 7-Methoxyflavone impedes the development of breast cancer and could be used as a chemoprevention agent. It may also boost testosterone levels. Know more about #7Methoxyflavone click the link below 👇 https://lnkd.in/gczu8ud6
To view or add a comment, sign in
-
Happy New Year from the WISDOM Study! #WISDOM #Breastcancerscreening #Happynewyear! To learn more about the WISDOM Study and personalized breast cancer screening, go to thewisdomstudy.org
To view or add a comment, sign in
-
📣For ESMO members: Breaking Science in #BreastCancer. Komal Jhaveri talks about the efficacy and safety of antibody-drug conjugates in metastatic breast cancer. 👉 Don't miss this video and others from the series on OncologyPRO. 🔗 https://ow.ly/444550Smp5L #ESMOBreast24
To view or add a comment, sign in
-
Dive into Dr Elisa Agostinetto’s analysis of the PALLAS study at #SABCS2023, exploring the interplay between palbociclib and PPIs in breast cancer treatment. Discover how these drug-drug interactions impact clinical outcomes. Discover these vital insights. 👇 For all SABCS 2023 videos, find the link in the comments! #MediMix #BreastCancerTreatment #OncologyInsights
To view or add a comment, sign in
-
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer : ALINA Trial Published April 10, 2024 N Engl J Med 2024;390:1265-1276 DOI: 10.1056/NEJMoa2310532
To view or add a comment, sign in
13,578 followers